DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
OSU-6162 is an investigational drug.
There have been 7 clinical trials for OSU-6162. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2007.
The most common disease conditions in clinical trials are Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, and Alzheimer Disease. The leading clinical trial sponsors are VA Office of Research and Development, Ohio State University, and Mayo Clinic.
Recent Clinical Trials for OSU-6162
|Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans||Tammie L. S. Benzinger, MD, PhD|
|Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans||Washington University School of Medicine|
|Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma||Johns Hopkins University||Early Phase 1|